Ralph Snyderman, former chancellor for health affairs and CEO of Duke University Health System, is joining the board at SenGenix, a startup in Durham that is commercializing technology developed at Duke.
Dr. Snyderman, an MD, also will serve as an advisor to the company.
SenGenix is developing medical diagnostics technology based on fluorescently responsive sensors for point-of-care testing.
“Dr. Snyderman’s experience in clinical medicine, biotechnology research and industry is an exceptional asset for SenGenix in commercializing its protein engineering technologies for fast, highly accurate and low cost point-of care testing,” said Lawrence Cohen, the chief executive officer at SenGenix. “Dr. Snyderman’s global reputation as a health system executive, clinician and researcher will help SenGenix build strong relationships with clinical investigators, physicians and hospital executives as we move forward in product development and into global market introduction.”
Sengenix launched earlier this year,
The firm relies on protein engineering as a platform for patient tests. The tests can be utilized in a variety of environments, including disaster sites, in ambulances and at physician offices.
The fluorescently responsive sensors are printed on test strips. These “provide easy, highly accurate results in seconds with just a drop of blood,” the company says. “Unlike other point-of-care testing systems, no expensive sampling cartridges or reader instruments are required with SenGenix technology.”
